China Pharma Holdings, Inc. — Q2 2013 Form 10-Q
Reporting period: Three and six months ended June 30, 2013; unaudited. The company manufactures and markets pharmaceutical products in China, primarily through its wholly owned PRC subsidiary, Helpson.
Financial results
| Metric | Q2 2013 | Q2 2012 | Six months 2013 | Six months 2012 |
|---|---|---|---|---|
| Revenue | $8.03 million | $14.60 million | $16.28 million | $30.69 million |
| Gross profit | $2.15 million | $4.14 million | $0.58 million | $9.44 million |
| Operating income (loss) | ($4.76 million) | $2.21 million | ($7.76 million) | $5.62 million |
| Net income (loss) | ($4.46 million) | $1.76 million | ($7.28 million) | $4.57 million |
| Basic and diluted EPS | ($0.10) | $0.04 | ($0.17) | $0.10 |
Q2 gross margin was approximately 27%, versus 28% a year earlier. First-half reported gross margin was approximately 3.6%, versus 30.8% in 2012; management said the $3.72 million inventory-obsolescence charge reduced first-half gross profit, and estimated gross profit of about $4.3 million and margin of 26% excluding that charge.
For the first half, operating cash flow was $3.06 million, investing cash flow was negative $4.62 million, and financing cash flow was zero. Cash and cash equivalents declined by $1.51 million to $2.52 million. The company also held $1.71 million in banker’s acceptances, which are not included in cash equivalents. The filing notes that treating certain longer-maturity acceptances as cash equivalents would have increased operating cash flow by $4.7 million.
At June 30, current assets were $101.12 million and current liabilities were $14.52 million. Net trade receivables were $55.36 million, with a $9.20 million doubtful-account allowance; inventory was $33.71 million after a $5.57 million obsolescence reserve. Short-term notes payable were $4.86 million, the outstanding balance on a bank line with no remaining availability. Total liabilities were $14.65 million.
Material changes and notable items
- Revenue fell 45% in Q2 and 47% in the first half. Management attributed the decline to tighter distributor credit and customer screening to improve collections, lower sales of major antibiotics and Gastrodin, and the cessation of Buflomedil sales.
- In March, China’s food and drug regulator ordered production, sale, and use of Buflomedil to cease. The company stopped related activity, recorded a $3.72 million inventory charge, and recognized $27,507 of customer refunds as a reduction of first-half revenue.
- First-half bad-debt expense was $4.63 million, compared with $0.55 million in 2012. Management reported $50.3 million of receivables more than 90 days past due; 8.1% of receivables were over 720 days old. It said it had not historically written off receivables, but increased its allowance as balances aged.
- Construction in progress rose as the company built a new production facility and upgraded manufacturing lines. Property and equipment, net, increased to $15.40 million from $9.03 million at year-end.
Outlook, risks, and contingencies
- Management expected operating cash flow, short-term borrowing, and the construction facility to fund working capital and anticipated spending for the next 12 months, while cautioning that failure to meet its operating plan could require additional financing or spending cuts.
- A subsequent event: on July 11, 2013, the company drew RMB 30 million (about $4.86 million) under an RMB 80 million (about $13 million), eight-year construction loan facility. The loan bears an initial 7.205% rate, has interest-only payments for two years, and requires the full facility to be drawn by December 31, 2014.
- Mandatory GMP upgrades to two injectable product lines were due by the end of 2013. Management expected completion but warned that delays could materially harm results. Pipeline timing also faces longer CFDA approval processes; Candesartan had received production approval, with launch planned for 2013.
- The company had about $7.1 million of milestone-based formula-development payments due over approximately four years, plus approximately $10.0 million of minimum construction and purchase commitments for 2013–2014.
- Risks include slow collections and aging receivables, continuing pricing pressure, reliance on PRC operations and customers, currency conversion and remittance restrictions, regulatory delays, and customer and supplier concentration. Two customers represented 10.3% and 10.2% of first-half sales; one supplier represented 26.9% of raw-material purchases.
The company reported effective disclosure controls and no material changes to internal control over financial reporting during the quarter. No formal financial guidance was provided.
Investor verification priorities
- Reconcile receivables aging, collections after quarter-end, and the adequacy of the $9.20 million allowance, particularly for balances over 720 days.
- Assess the drivers and sustainability of the revenue decline, including the impact of tighter credit policies and lost Buflomedil sales.
- Confirm the inventory reserve and whether the reported first-half margin excluding the obsolescence charge is a useful indicator of ongoing economics.
- Track GMP upgrade completion, required spending, construction-loan drawdowns and terms, and the ability to meet construction and formula-development commitments.
- Review the timing and commercial prospects of pipeline products and the effect of changing CFDA approval requirements.